Revumenib

A small molecule inhibitor used in cancer treatment

Revumenib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Revumenib is a small molecule inhibitor that targets the menin-MLL interaction, which is implicated in certain types of acute leukemia. It is primarily being investigated for its potential use in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations.

Mechanism of Action

Revumenib functions by inhibiting the interaction between menin, a protein that plays a role in gene expression regulation, and the mixed-lineage leukemia (MLL) protein. This interaction is crucial in the pathogenesis of leukemias that harbor MLL rearrangements. By disrupting this interaction, revumenib can potentially halt the proliferation of leukemic cells and induce differentiation.

Clinical Development

Revumenib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with MLL-rearranged leukemias. These trials aim to determine the optimal dosing regimen and to assess the drug's impact on survival rates and disease progression.

Pharmacokinetics

The pharmacokinetic profile of revumenib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects.

Potential Side Effects

As with many targeted therapies, revumenib may cause side effects, which can include gastrointestinal disturbances, fatigue, and hematological abnormalities. Ongoing studies are focused on identifying and managing these adverse effects to improve patient outcomes.

Research and Future Directions

Research on revumenib is expanding to explore its use in combination with other therapies, such as chemotherapy and immunotherapy, to enhance its efficacy. Additionally, studies are investigating its potential application in other malignancies with similar genetic profiles.

Related Pages

• Acute myeloid leukemia
• Acute lymphoblastic leukemia
• Menin-MLL interaction
• Targeted therapy